Powder-filled capsules are eminently suitable for both early-stage development and commercial use. We have the capability to insert an API directly for Phase I (First in Man) studies, allowing a clinical product to be produced quickly with minimal development and using very little API.
We also have considerable expertise in developing bespoke formulations for powder-filled capsules. We have a particular interest in working with APIs that present challenging properties such as low bioavailability or solubility, or that require low dosage levels or low bulk density in the capsule.
Alongside our powder filled capsule capabilities, we are experienced in developing liquid or semi-solid formulations for use in capsules. These lipidic formulations have many advantages over the standard powder fill approach, particularly for improving bioavailability.